diethyl <4-(benzyloxy)benzyl>phosphonate | 131719-55-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: diethyl <4-(benzyloxy)benzyl>phosphonate
• 英文别名: (4-benzyloxybenzyl)-phosphonic acid diethyl ester；4-(benzyloxy)-1-(diethylphosphonomethyl)benzene；4-Benzyloxy-benzyldiaethylphosphonat；Diethyl 4-(benzyloxy)benzylphosphonate；1-(diethoxyphosphorylmethyl)-4-phenylmethoxybenzene
• CAS: 131719-55-6
• 化学式: C₁₈H₂₃O₄P
• 分子量: 334.352
• InChiKey: LOPTXROLMDAJBT-UHFFFAOYSA-N

物化性质

• 沸点：
  466.0±33.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  diethyl <4-(benzyloxy)benzyl>phosphonate 在 三氯化铝 、 sodium hydride 、 N,N-二甲基苯胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 白藜芦醇
  参考文献：
  名称：

  Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogs of piceatannol

  摘要：

  A series of hydroxylated trans-stilbenes related to the antileukemic natural product trans-3,3',4,5'-tetrahydroxystilbene (piceatannol) (1) has been prepared and tested for inhibition of the lymphoid cell lineage-specific protein-tyrosine kinase p56lck, which plays an important role in lymphocyte proliferation and immune function. A number of the analogues displayed enhanced enzyme inhibitory activity relative to the natural product. Reduction of the double bond bridging the two aromatic rings and benzylation of the phenolic hydroxyl groups was found to decrease activity significantly. The most potent compounds in the series proved to be trans-3,3',5,5'-tetrahydroxystilbene, trans-3,3',5-trihydroxystilbene, and trans-3,4,4'-trihydroxystilbene.

  DOI：

  10.1021/jm00072a015
• 作为产物：
  描述：

  4-苄氧基苯甲醛 在 sodium tetrahydroborate 、 三溴化磷 、 四丁基碘化铵 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 17.0h， 生成 diethyl <4-(benzyloxy)benzyl>phosphonate
  参考文献：
  名称：

  Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogs of piceatannol

  摘要：

  A series of hydroxylated trans-stilbenes related to the antileukemic natural product trans-3,3',4,5'-tetrahydroxystilbene (piceatannol) (1) has been prepared and tested for inhibition of the lymphoid cell lineage-specific protein-tyrosine kinase p56lck, which plays an important role in lymphocyte proliferation and immune function. A number of the analogues displayed enhanced enzyme inhibitory activity relative to the natural product. Reduction of the double bond bridging the two aromatic rings and benzylation of the phenolic hydroxyl groups was found to decrease activity significantly. The most potent compounds in the series proved to be trans-3,3',5,5'-tetrahydroxystilbene, trans-3,3',5-trihydroxystilbene, and trans-3,4,4'-trihydroxystilbene.

  DOI：

  10.1021/jm00072a015

文献信息

• Novel Phosphinic Acid-Containing Thyromimetics
  申请人：Erion Mark D.

  公开号：US20090028925A1

  公开（公告）日：2009-01-29

  The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

  本发明涉及含有磷酸基T3拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟拟
• Efficient synthesis of small-sized phosphonated dendrons: potential organic coatings of iron oxide nanoparticles
  作者：Antonio Garofalo、Audrey Parat、Catalina Bordeianu、Cynthia Ghobril、Marie Kueny-Stotz、Aurélie Walter、Julien Jouhannaud、Sylvie Begin-Colin、Delphine Felder-Flesch

  DOI：10.1039/c4nj00654b

  日期：——

  We report herein the synthesis of biocompatible small-sized phosphonated monomers and dendrons used as functional coatings of metal oxide nanoparticles, more specifically superparamagnetic iron oxides (SPIOs) for magnetic resonance imaging (MRI) and therapy through hyperthermia. The molecules were engineered to modulate their size, their hydrophilic and/or biocompatible character (poly(amido)amine versus oligoethyleneglycol), the number of anchoring phosphonate groups (monophosphonate versus phosphonic tweezers) and the number of peripheral functional groups for further grafting of dyes or specific vectors. Such a library of hydrophilic phosphonic acids opens new possibilities for the investigation of dendronized nanohybrids as theranostics.

  我们在此报道了一种生物相容性的、尺寸较小的膦酸化单体和树枝状大分子的合成，这些物质作为金属氧化物纳米颗粒的功能性涂层，更具体地说是用于磁共振成像（MRI）和通过高温治疗的铁磁性氧化物（SPIOs）。这些分子被设计用来调节它们的大小、亲水性和/或生物相容性特征（聚酰胺胺vs.寡聚乙二醇）、锚定的膦酸基团的数量（单膦酸vs.膦酸钳）以及外围功能性基团的数量，以便进一步接枝染料或特定的载体。这样一个亲水性膦酸库为研究作为治疗诊断一体化的树枝状纳米杂化物开辟了新的可能性。
• [EN] PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF<br/>[FR] COMPOSÉ D'ACIDE PHOSPHONIQUE ET PROMÉDICAMENT DE CELUI-CI, PROCÉDÉS DE PRÉPARATION ET UTILISATIONS D'UN COMPOSÉ D'ACIDE PHOSPHONIQUE ET D'UN PROMÉDICAMENT DE CELUI-CI<br/>[ZH] 膦酸类化合物及其前药、它们的制备方法及用途
  申请人：[en]HAIHE BIOPHARMA CO., LTD.;[zh]上海海和药物研究开发股份有限公司

  公开号：WO2023138637A1

  公开（公告）日：2023-07-27

  本发明提供膦酸类化合物及其前药、它们的制备方法及用途。具体地，本发明提供下式(I)或式(I-A)的化合物，其中，式(I-A)的化合物为式(I)化合物的前药形式。经实验验证，本发明的膦酸类化合物具有良好的ENPP1激酶抑制活性，可作为ENPP1相关疾病的治疗剂，并且所述膦酸类化合物具有良好的体内代谢稳定性。此外，本发明提供的膦酸酯类或酰胺类前药化合物具有较高的口服生物利用度，可以克服膦酸类原药化合物不能口服的缺陷。
• [EN] NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS<br/>[FR] NOUVELLES SUBSTANCES THYROMIMETIQUES CONTENANT DU PHOSPHORE
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2005051298A3

  公开（公告）日：2005-08-11
• Synthesis and Biological Evaluation of a Series of Liver-Selective Phosphonic Acid Thyroid Hormone Receptor Agonists and Their Prodrugs
  作者：Serge H. Boyer、Hongjian Jiang、Jason D. Jacintho、Mali Venkat Reddy、Haiqing Li、Wenyu Li、Jennifer L. Godwin、William G. Schulz、Edward E. Cable、Jinzhao Hou、Rongrong Wu、James M. Fujitaki、Scott J. Hecker、Mark D. Erion

  DOI：10.1021/jm800824d

  日期：2008.11.27

  Phosphonic acid (PA) thyroid hormone receptor (TR) agonists were synthesized to exploit the poor distribution of PA-based drugs to extrahepatic tissues and thereby to improve the therapeutic index. Nine PAs showed excellent TR binding affinities (TR beta(1), K-i < 10 nM), and most of them demonstrated significant cholesterol lowering effects in a cholesterol-fed rat (CFR) model. Unlike the corresponding carboxylic acid analogue and T-3, PA 22c demonstrated liver-selective effects by inducing maximal mitochondrial glycerol-3-phosphate dehydrogenase activity in rat liver while having no effect in the heart. Because of the low oral bioavailability of PA 22c, a series of prodrugs was synthesized and screened for oral efficacy in the CFR assay. The liver-activated cyclic 1-(3-chlorophenyl)-1,3-propanyl prodrug (MB07811) showed potent lipid lowering activity in the CFR (ED50 0.4 mg/kg, po) and good oral bioavailability (40%, rat) and was selected for development for the treatment of hypercholesterolemia.